Welcome to Shanghai Probechem Biochemicals Co Ltd !Global Supplier of Chemical Probes, Inhibitors & Agonists.
Chemical Structure : CUDC-907
CAS No.: 1339928-25-4
Catalog No.: PC-49141Not For Human Use, Lab Use Only.
Fimepinostat (CUDC-907) is a potent, dual-acting PI3K and HDAC inhibitor, potently inhibits HDAC classes I and II enzymes, inhibits class I PI3K kinases with IC50 of 19, 54, and 39 nM for PI3Kα, PI3Kβ, and PI3Kδ, respectively.
| Packing | Price | Stock | Quantity |
|---|---|---|---|
| 25 mg | $188 | In stock | |
| 50 mg | $298 | In stock | |
| 100 mg | $528 | In stock | |
| 200 mg | Get quote | ||
| 1 g | Get quote |
Bulk size, bulk discount!
E-mail: sales@probechem.com
Tech Support: tech@probechem.com
Fimepinostat (CUDC-907) is a potent, dual-acting PI3K and HDAC inhibitor, potently inhibits HDAC classes I and II enzymes, inhibits class I PI3K kinases with IC50 of 19, 54, and 39 nM for PI3Kα, PI3Kβ, and PI3Kδ, respectively.
CUDC-907 inhibitsthe PI3K pathway, as indicated by the dose-dependent decreases in phosphorylation of AKT and its downstream targets, 4EBP-1 and p70S6, in H460 cells.
CUDC-907 durably suppresses activation of AKT and modulates receptor tyrosine kinase, RAF-MEK-MAPK and SRC/STAT signaling via HDAC inhibition, downregulates and suppresses the activation of the SRC/STAT signaling pathway and multiple receptor tyrosine kinases.
CUDC-907 induces apoptosis and G2-M cell-cycle arrest in cancer cells, and effectively inhibits cancer cell growth (MOLT4 cell, IC50=1 nM).
CUDC-907 (25, 50, and 100 mg/kg, oral) suppresses tumor growth, inhibits HDAC activity, and blocks signaling of PI3K and MAPK pathways in xenograft models.
CUDC-907 (500 nM) exhibits enhanced adipocytic differentiation in human bone marrow stromal cells (hBMSCs).
| M.Wt | 508.557 | |
| Formula | C23H24N8O4S | |
| Appearance | Solid | |
| Storage |
|
|
| Solubility |
10 mM in DMSO |
|
| Chemical Name/SMILES |
N-hydroxy-2-[[[2-(6-methoxy-3-pyridinyl)-4-(4-morpholinyl)thieno[3,2-d]pyrimidin-6-yl]methyl]methylamino]-5-pyrimidinecarboxamide |
|
1. Qian C, et al. Clin Cancer Res. 2012 Aug 1;18(15):4104-13.
2. Sun K, et al. Mol Cancer Ther. 2017 Feb;16(2):285-299.
3. Ali D, et al. Stem Cells Dev. 2017 Mar 1;26(5):353-362.
Copyright © 2022 probechem.com. All Rights Reserved. probechem Copyright
